Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) announced that Panetta Partners Limited acquired 20,000 common shares at $0.75 each, increasing Executive Chairman Gabriele Cerrone's ownership from 37.60% to 37.61%. Tiziana is focused on developing innovative immunotherapies through novel drug delivery methods, including intranasal and oral routes, which show potential for better efficacy and safety compared to traditional IV methods. Their lead candidates, intranasal foralumab and milciclib, have shown favorable safety profiles and clinical responses in studies.

Positive

• Executive Chairman Gabriele Cerrone increased his ownership stake marginally to 37.61%.
• Tiziana is developing novel immunotherapy delivery methods that may offer improved efficacy and safety.

Negative

• None.

NEW YORK, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 20,000 common shares at $0.75 per share.

The acquisition takes Mr Cerrone's interests from 37.60% to 37.61%.

About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further inquiries:

Tiziana Life Sciences Ltd Hana Malik, Business Development, and Investor Relations Manager   +44 (0) 207 495 2379 email: info@tizianalifesciences.com
Investors: Irina Koffler LifeSci Advisors, LLC 646.970.4681 ikoffler@lifesciadvisors.com

 

FAQ

What recent acquisition did Tiziana Life Sciences announce?

Tiziana Life Sciences announced that Panetta Partners Limited acquired 20,000 common shares at $0.75 each.

How much did Gabriele Cerrone's stake in Tiziana Life Sciences increase?

Gabriele Cerrone's stake increased from 37.60% to 37.61% following the acquisition.

What are Tiziana's lead drug candidates?

Tiziana's lead candidates are intranasal foralumab, a fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor.

What innovative delivery methods is Tiziana Life Sciences developing?

Tiziana is developing nasal, oral, and inhalation drug delivery methods to enhance immunotherapy.